Erratum: 2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells (Blood (2009) 114:6 (1217-1225) DOI: 10.1182/blood-2008-11-190587);2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells

Blood

Volumn 114, Issue 6, 2009, Pages 1217-1225

  Steele, Andrew J ^a   Prentice, Archibald G ^a   Hoffbrand, A Victor ^a   Yogashangary, Birunthini C ^a   Hart, Stephen M ^a   Lowdell, Mark W ^a   Samuel, Edward R ^a   North, Janet M ^a   Nacheva, Elisabeth P ^a   Chanalaris, Anastasios ^a   Kottaridis, Panagiotis ^a   Cwynarski, Kate ^a   Wickremasinghe, R Gitendra ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYLACETYLENESULFONAMIDE; CASPASE 3; CYTOCHROME C; LIPOCORTIN 5; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN NOXA; PROTEIN P53; SULFONAMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; PMAIP1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CELL DEATH; CELL ISOLATION; CELL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOSOL; DRUG ACTIVITY; ENZYME ACTIVATION; GENE DELETION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN SECRETION; STAINING; UPREGULATION; AGED; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN TRANSPORT; T LYMPHOCYTE; TIME; TUMOR CELL CULTURE;

AGED; AGED, 80 AND OVER; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CYTOCHROMES C; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOCHONDRIA; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; T-LYMPHOCYTES; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 69849089290     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood.2019002453     Document Type: Erratum

References (52)

1. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755-764. (Pubitemid 40322252)
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
3. Rassenti LZ, Jain S, Keating MJ, et al. Relative values of ZAP-70, CD38 and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112:1923-1930.
4. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916. (Pubitemid 32064784)
5. Barlow C, Brown KD, Deng CX, Tagle DA, Wynshaw-Boris A. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet. 1997;17:453-456. (Pubitemid 27518396)
6. Cordone C, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91:4342-4349. (Pubitemid 28261999)
7. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IgVH mutational status and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-1184.
8. Grever MR, Lucas DM, Johnson AJ, Byrd JC. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007;20:545-556. (Pubitemid 47250499)
9. Fenaux P, Preudhomme C, Lai JL, et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia. 1992;6:246-250.
10. El Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993;82:3452-3459. (Pubitemid 23356719)
11. Barnabas N, Shurafa M, Van Dyke DL, et al. Significance of p53 mutations in patients with chronic lymphocytic leukemia; a sequential study of 30 patients. Cancer. 2001;91:285-293. (Pubitemid 32099228)
12. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007;370:230-239. (Pubitemid 47069536)
13. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 deletions and mutations. Blood. 2004;103:3278-3281. (Pubitemid 38525651)
14. Osuji NC, Del Iudice I, Matutes E, et al. the efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Hematologica. 2005;90:1435-1436. (Pubitemid 41503660)
15. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose prednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia. 2006;20:1441-1445. (Pubitemid 44084061)
16. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007:1324-1337 (Pubitemid 46328466)
17. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8:121-132.
18. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117:112-121 (Pubitemid 46048458)
19. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem. 2004;279:8627-8634. (Pubitemid 38295917)
20. Nikiforov MA, Roblett M, Tang WH, et al. Tumor cell-selective regulation of NOXA by c-Myc in response to proteasome inhibition. Proc Natl Acad Sci U S A. 2007;104:19488-19493.
21. Obexer P, Geiger K, Ambros PF, Meister B, Ausserlecjhner MJ. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cell. Cell Death Differ. 2007;14:534-547. (Pubitemid 46259961)
22. Schuler M, Green DR. Transcription, apoptosis and p53: catch 22. Trends Genet. 2005;21:182-187.
23. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;285:1053-1058. (Pubitemid 30324238)
24. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683-694. (Pubitemid 32706359)
25. Johnston JB, Daeninck P, Verburg L, et al. p53, MDM-2, BAX, BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymph. 1997;26:435-449. (Pubitemid 27477770)
26. Morabito F, Filangeri M, Callea I, et al. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Hematologica. 1997;82:16-20. (Pubitemid 28023481)
27. Panasci L, Paiement JP, Christodoulopoulos G, et al. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res. 2001;7:454-461. (Pubitemid 32707964)
28. Strom E, Sathe S, Komarov PG, et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol. 2006;2:474-479. (Pubitemid 44266309)
29. Jones DT, Ganeshaguru K, Virchis AE, et al. Caspase 8 activation independent of Fas(CD95/APO-1) signalling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood. 2001;98:2800-2807.
30. Jones DT, Addison E, North JM, et al. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augments the cells' sensitivity to cytotoxic drugs. Blood. 2004;103:1855-1861. (Pubitemid 38268983)
31. Liu FT, Newland AC, Jia L. Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. Biochem Biophys Res Commun. 2003;310:956-962. (Pubitemid 37188715)
32. Steele AJ, Prentice AG, Hoffbrand AV, et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanisms. Blood. 2008;112:3827-3834.
33. Ramsby ML, Makowski GS. Differential detergent fractionation of eukaryotic cells. Methods Mol Biol. 1999;112:53-66.
34. Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood. 2003;102:652-658. (Pubitemid 36841988)
35. Koopman G, Reuterlingsperger CP, Kuijten GA, et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415-1420. (Pubitemid 24273007)
36. Posovszky C, Friesen C, Herr I, Debatin KM. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia. 1999;13:400-409. (Pubitemid 29108079)
37. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53:3976-3985. (Pubitemid 23267698)
38. Jones DT, Ganeshaguru K, Anderson RA, et al. Albumin activates the AKT signalling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. Blood. 2003;101:3174-3180. (Pubitemid 36858012)
39. Cotter TG, Lennon SV, Glynn JG, Martin SJ. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res. 1990;10:1153-1159.
40. Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia. 2007;21:1773-1782. (Pubitemid 47086766)
41. Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007;109:1660-1668. (Pubitemid 46242110)
42. Masdehors P, Merle-Béral H, Maloum K, Omura S, Magdelénat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 2000;9:269-274 (Pubitemid 30456481)
43. Iglesias-Serret D, de Frias M, Santidrián AF, et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia. 2007;21:281-287 (Pubitemid 46158121)
44. Erlacher M, Michalak EM, Kelly PN, et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis. Blood. 2005;106:4131-4138.
45. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;312:1036-1038. (Pubitemid 37386194)
46. Shibue T, Takeda K, Oda e, et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2003;17:2233-2238. (Pubitemid 37128638)
47. Michalak EM, Villunger A, Adams JM, Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008;15:1019-1029. (Pubitemid 351712606)
48. Naik E, Michalak EM, Villunger A, Adams JM, Strasser A. Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa. J Cell Biol. 2007;176:415-424. (Pubitemid 46257269)
49. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:415-424. (Pubitemid 40193310)
50. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ. 2006;994-1002.
51. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 2003;4:371-381. (Pubitemid 37491098)
52. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;17:525-535. (Pubitemid 36385115)